Bridge to Life Wins Canada License, FDA Breakthrough Status
Duluth, Georgia, USA, November 3, 2026 Bridge to Life⢠Ltd., a global innovator in organ preservation solutions and perfusion...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Duluth, Georgia, USA, November 3, 2026 Bridge to Life⢠Ltd., a global innovator in organ preservation solutions and perfusion...
DULUTH, Ga., June 23, 2026 Bridge to Life Ltd. announced new investigator-initiated research presented at the 2026 American Transplant...
DULUTH, Georgia, May 28, 2026 Bridge to Life⢠Ltd. has announced the publication of landmark clinical trial results in...
